Pegaspargase
Pegaspargase //, trade name Oncaspar, is a modified enzyme used as an antineoplastic agent. It is a form of L-asparaginase[1] which has undergone PEGylation.
It is used in the treatment of acute lymphoblastic leukemia.[2][3]
See also
PEGylation
References
- ↑ "UNM Cancer Center". Retrieved 2007-08-28.
- ↑ Graham ML (2003). "Pegaspargase: a review of clinical studies". Adv. Drug Deliv. Rev. 55 (10): 1293–302. doi:10.1016/S0169-409X(03)00110-8. PMID 14499708.
- ↑ Patel SS, Benfield P (Jun 1996). "New drug profile: pegaspargase (Polyethylene Glycol L-Asparaginase)". Clinical Immunotherapeutics 5 (6): 492–496.
|
---|
| SPs/MIs (M phase) | | |
---|
| Block microtubule disassembly | |
---|
|
---|
| DNA replication inhibitor | |
---|
| Photosensitizers/PDT | |
---|
| Other | |
---|
| |
---|
| Description |
- Tumor suppressing and oncogenes
- Tumor markers
- Carcinogen
|
---|
| Disease |
- Neoplasms and cancer
- Symptoms and signs
- Paraneoplastic
|
---|
| Treatment |
- Radiotherapy
- Drugs
- Immunotherapy
- intracellular chemotherapeutics
- extracellular chemotherapeutics
- adjuvant detoxification
|
---|
|
|